authors
-
Anna Brandys, Marek Pawlicki
- Z Kliniki Chemioterapii Instytutu Onkologii w Krakowie
Kierownik Kliniki: Prof. dr hab, med. M. Pawlicki
Z Przychodni Chemioterapii Instytutu Onkologii w Krakowie
Kierownik Przychodni: Lek. med. A. Brandys
Dyrektor Instytutu Onkologii w Krakowie: Prof. dr hab. med. Jan Skołyszewski
summary
- Group of 139 patients with kidney cancer have been paliatively treated with systemic
- chemotherapy — 53 patients, with hormonotherapy — 64 patients, and Immunotherapy — 24
- patients.
- The aim of the investigation was evaluation of cffectiveness of paliative treatment and
- emerging the group of patients in whom this kind of treatment may be effective. Criteria of
- effectiveness are: remision time and survival time.
- Remarkable remision time has been achieved only in patients with lung metastasis after
- nephrectomy. Immunotherapy has been proved to be the most successful method of treatment.
- Treatment of primary rion-operatiw kidney cancer seeMs tO be useless.
references
- 1. Bergerat J.P., Herbiecht R., Durfour P. el al: \\\"Combination of recombinat interferon alpha-2a and vinblastine in advanced renal cell cancer\\\". — Cancer 1988, 62: 2330-4, —
- 2 Decernino JB. et al: \\\"Treatment of advanced renal cell carcinoma\\\", in: Kuss R. et al: \\\"Renal tumors. A.R. Liss, New York, 1982, 641-59. —
- 3. Fossa SD. et al: \\\"Recombinat interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma\\\". Cancer 57: 1700-704, 196.
- 4. Frank I.N., Graham S.D., Nabors /_.: \\\"Urological and male grnital cancer\\\", Clinical Oncology ACST ed.: Holled A.J., Fink D. J., Murphy G.P., 1991. —
- 5 Neidhart J.A.: \\\"interferon therapy for the treatment of renal Cancer Cancer 57: 1969 - 699, 1986. —
- 6. Miller szp. 19 MA A.B., Hoogstraten B , Sta±uet Al., Winkler A.: \\\"Raporting results of cancer treatment\\\".Cancer 47: 207, 1981. —
- 7. Rosenberg S.A., Lot ze L.M., et al: \\\"A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone\\\". N Engl. J. Med. 1987: 316, 889- 97. —
- 8. Steineck G., Strander H., Carbin B.Ii. et al: Recombinat leucocyte interferon alpha-2a ang medroxyprogesterone in advanced renal cell carcinoma, a randomized trial\\\". Acta Oncologica 1990: 155-62.
correspondence
Anna Brandys
30-058 Kraków, ul. Lea 93/99 m. 58
|